CCW702 *

CCW702 is an investigational immunotherapy for metastatic castration resistant prostate cancer being developed by Calibr in a first-in-patient clinical trial. AbbVie holds an option to license the program at the conclusion of the trial.

 

Type of Molecule

Biologic

Target

CD3-PSMA

Product Type

New Indication
Potential Indication Region Phase (1, 2, 3, Submitted, Approved)
Prostate Cancer n/a
Phase 1